Peptide binding to ochratoxin A mycotoxin: a new approach in conception of biosensors.

Ingrid Bazin, Nicolas Andreotti, Aziza Ibn Hadj Hassine, Michel de Waard, Jean-Marc Sabatier, Catherine Gonzalez

1   **Peptide binding to ochratoxin A mycotoxin: a new approach in conception of biosensors.**

2   I. Bazin[a*], N. Andreotti[b], A. Ibn Hadj Hassine[a], M. De Waard[c], J.M. Sabatier[b], C.

3   Gonzalez[a]

4   [a]Ecole des Mines d'Ales, 6 avenue de Claviers 30319 Ales cedex.

5   [b]INSERM UMR1097, Aix-Marseille Université, Parc scientifique de Luminy, Marseille,
6   France.

7   [c]INSERM U836, Grenoble Institut des Neurosciences, Bâtiment Edmond Safra, 38042
8   Grenoble Cedex 09, France.

9   *Corresponding author: ingrid.bazin@mines-ales.fr

10   **Abstract**

11   Ochratoxin A (OTA) is a widespread and abundant natural carcinogenic mycotoxin produced

12   by several species of *Aspergillus* and *Penicillium* fungi. Due to the ubiquitous presence of

13   these fungi in food and potential risk for human health, a rapid and sensitive *in vitro* detection

14   assay is required. Analytical methods for OTA detection/identification are generally based on

15   liquid–liquid extraction, clean-up using an immunoaffinity column (IAC), and identification

16   by reversed-phase high pressure liquid chromatography with fluorescence detection (HPLC-

17   FLD). However, IACs are costly and have a short lifespan. Therefore, an interesting approach

18   would appear to be the design and chemical synthesis of a mimotope peptide simulating

19   mycotoxin-specific antibodies. We have developed a promising alternative method that is

20   based on the use of peptides which are able to bind to specific chemical functions and/or

21   molecular structures. Accordingly, a number of peptides (derived from the structures of major

22   redox proteins) were selected and produced by chemical solid phase syntheses. The ability of

23   such peptides to bind to ochratoxin A was evaluated by HPLC. The peptide NF04

24   (structurally derived from an oxidoreductase enzyme), which was found to be the sole

25   potently reactive compound among tested molecules, was further evaluated in a peptide-based

26   enzyme-linked immunosorbent assay (peptide-based ELISA), thus confirming its specific

27   interaction with ochratoxin A.

28   **Keywords:** peptide binding, peptide-based assay, ochratoxin A, mycotoxin

29

30   1. Introduction

31 Ochratoxin A, also referred to as OTA, is a coumarinic mycotoxin produced by several fungi

32 species from *Aspergillus* (e.g., *A. ochraceus*) and *Penicillium* (e.g., *P. verrucosum*) genera

33 under different environmental conditions (Scott et al., 1997; Brera et al., 2008). It is a

34 mycotoxin that has been identified as a contaminant in grains, cereals, beans, coffee, dried

35 fruits and wine (Zimmerli et al., 1995, Varga et al., 2006; Blessa et al., 2006). OTA is known

36 to have nephrotoxic, immunotoxic, teratogenic and carcinogenic effects (O'Brien et al., 2005,

37 Pfohl-Leszkowicz et al., 2002, Smith et al., 1995). Wine contamination by OTA has been

38 described and largely reviewed by several authors (Varga et al., 2006; Blessa et al., 2006).

39 This beverage is widely consumed and represents a major source of daily OTA intake for the

40 population (Jorgensen et al., 2005). Thus, regulatory limits for OTA exist in many countries,

41 especially in Europe where maximum limits for OTA in wine, grape juices and grape

42 beverages, have been fixed at 2 µg l^{-1} (European Union, 2005, 2010). Nowadays, the most

43 widely used quality control process relies on an immunoaffinity column (IAC), followed by

44 reversed-phase high pressure liquid chromatography using fluorescence detection (HPLC-

45 FLD) (Visconti et al., 1999, Aresta et al., 2006). Because this mycotoxin is largely

46 represented in food, availability of rapid, reliable and sensitive analytical methods for the

47 detection of OTA is required to protect consumers' health. Despite the fact that the IAC

48 procedure is rather simple, sensitive and quite reproducible, IACs are unfortunately too costly,

49 together with short shelf lives. In the last decade, several groups attempted to develop

50 appropriate alternative assays to improve rapidity and sensitivity, combined with cost

51 reduction. Such methods rely on immunoassays, test strips and biosensors. First, a

52 competitive ELISA kit has been used widely in recent years for the detection of OTA.

53 ELISAs for ochratoxin content analyses have been reported in barley (Morgan et al., 1983).

54 The assay sensitivity for detection of OTA in barley samples was circa 5 µg kg^{-1}

55 (Ramakrishna et al., 1990). Angelini et al., (2008) compared performance of four extraction

56 procedures and three commercial ELISA kits for OTA in grapes. Sometimes, IAC are used to

57 concentrate OTA. The advantage of using IAC after the extraction procedure was the

58 excellent detection limit, which was between 0.06 and 0.0075 µg l^{-1}. This detection limit

59 depends on the ELISA kit used. Second, the test strip, also called lateral flow device or

60 immunochromatographic strip (ICS) test, is based on a membrane loaded with immobilized

61 antibodies. They are of simple use and give faster results (2 to 15 min). Test strips are semi-

62 quantitative with different visual limits of detection (LOD) in function of the nature of sample

63 (Krska et al., 2009; Shim et al., 2009). Initially, the LOD was set at ca. 500 µg l^{-1} of OTA

64 (Cho et al., 2005; Rusanova et al., 2009), whereas, nowadays, the cutoff level dropped down

65 to 1 µg l^{-1}, which corresponds to the lower limit tolerated by the Food and Drugs

66 Administration. Third, with regard to biosensors, their characteristics depend on the nature of

67 the bioreceptor and the physical transducer. Antibodies, which show high selectivity and

68 affinity towards mycotoxins, have been widely used to set up a variety of immunosensors

69 (e.g. electrochemical, impedimetric or conductimetric immunosensors) against mycotoxins

70 like OTA (Pietro-Simon et al., 2008; Liu et al., 2009; Alacon et al., 2006; Radi et al., 2008

71 and 2009).

72 The well-known favorable molecular recognition characteristics of an antibody (in

73 terms of affinity and selectivity) are counterbalanced by the unfavorable use of different

74 matrix samples or experimental conditions of assay (e.g. denaturation of antibodies in organic

75 solvents). To overcome these drawbacks, several strategies have been followed such as

76 development of new synthetic systems that mimic the recognition properties of antibodies.

77 Indeed, many efforts have been made to substitute OTA antibodies by DNA aptamers (Cruz-

78 Aguado et al., 2008a, 2008b), molecularly imprinted polymers (MIP) (Ali et al., 2010; Yu et

79 al., 2010) and phage display libraries (Giraudi et al., 2007). The isolation of oligonucleotide

80 sequences (DNA aptamers) and synthetic receptor(s) (MIP) that recognize this class of target

81 molecules have some advantages compared to antibodies. They can be generated easily and

82 are stable at different pH values and/or at high temperatures. Among these approaches, based

83 on synthetic systems, none of them reach affinity for OTA that is compatible with the

84 detection limits fixed in wine by the European Commission (2.0 µg l^{-1}) or the rest of the

85 world (1.0 µg l^{-1}). The first hexapeptide selected using phage display libraries exhibits an

86 affinity of ca. 3.4 x 10^4 M^{-1} towards OTA (Giraudi et al., 2007). Although moderate, such a

87 peptide affinity can be potentially increased by some structure-activity relationship studies.

88 Peptide-based detection assays in general are commercially available and most frequently

89 used in the biomedical field rather than environmental sciences which is of concern in this

90 study. For examples, peptides are used in various fields, from diagnosis of HIV infection

91 (Alcaro et al., 2003; Ravanshad et al., 2006, Gerasimov 2010) to detection of potential

92 sensitizing compounds (Gerberik et al., 2004).

93 Apart from the previously described techniques used for OTA quantification, we describe in

94 this work for the first time a novel approach based on the identification of new peptides (not

95 based on phage display analyses) which exhibit significant affinities towards OTA. HPLC

96 was used as an analytical method to select the most potent peptide interacting with OTA in a

97 binding assay. Identification of such a peptide is important and allowed us to analyze some

98   red wine samples that were previously supplemented with OTA in a peptide-based enzyme-

99   linked immunosorbent assay (peptide-based ELISA).

100   2. Material and methods

101   *2.1.   Materials*

102   N^{α}-fluorenyl-9-methyloxycarbonyl (Fmoc)-L-amino acids, Fmoc-amide rink resin, and

103   reagents used for peptide synthesis were obtained from Iris Biotech (Germany). Solvents were

104   analytical grade products from Carlo-Erba (France).

105

106   *2.2.   Chemicals*

107   OTA was obtained from Sigma-Aldrich (France). A solution was prepared in methanol at 1

108   mg ml^{-1}. PEG 8000 (Polyethylene Glycol) and PVPP were obtained from Promega (France).

109   Luminol was obtained from Pierce (France).

110

111   *2.3.   Solid-Phase Peptide Synthesis*

112   The peptides (NF01, NF02, NF03, NF04, Chim1, pep01 and pep02) were produced by

113   chemical synthesis using a peptide synthesizer (Model 433A, Applied Biosystems Inc.). The

114   amino acid sequence of the most reactive peptide, i.e. NFO4, is provided in Fig. 2B. All

115   peptide sequences are described in European patent n° 12305269.8 (deposited by Tournoux

116   Biotech on March 5th 2012). Peptide chains were assembled stepwise on 0.25 mmol of Fmoc-

117   amide resin (1% cross-linked; 0.65 mmol of amino group/g) using 1 mmol of N^{α}-(9-

118   fluorenyl)methyloxycarbonyl (Fmoc) L-amino acid derivatives. Side chain-protecting groups

119   for trifunctional residues were: trityl for cysteine, and asparagine; *t*-butyl for tyrosine,

120   glutamate and aspartate; 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for arginine; and

121   *t*-butyloxycarbonyl for lysine. N^{α}-amino groups were deprotected by successively treating

122   with 18 and 20% (v/v) piperidine/N-methylpyrrolidone for 3 and 8 min, respectively. After

123   three washes with *N*-methylpyrrolidone, the Fmoc-amino acid derivatives were coupled (20

124   min) as their hydroxybenzotriazole active esters in *N*-methylpyrrolidone (4-fold excess). After

125   peptides were assembled, and removal of N-terminal Fmoc groups, the peptide resins (ca. 1.5

126   g) were treated under stirring for 2.5 h at 25°C with mixtures of trifluoroacetic

127   acid/H_2O/thioanisole/ethanedithiol (73:11:11:5, v/v) in the presence of crystalline phenol (2.1

128   g) in final volumes of 30 ml per gram of peptide resins. The peptide mixtures were filtered,

129   precipitated and washed twice with cold diethyloxide. The crude peptides were pelleted by

130   centrifugation (3,200 × g; 10 min). They were then dissolved in H_2O and freeze dried. The

131 crude peptides were purified to homogeneity by reversed-phase high pressure liquid
132 chromatography (HPLC) (C_{18} Aquapore ODS, 20 μm, 250 × 10 mm; PerkinElmer Life
133 Sciences) by means of a 60-min linear gradient of 0.08% (v/v) trifluoroacetic acid/H_2O
134 (buffer A) with 0 to 40% of 0.1% (v/v) trifluoroacetic acid/acetonitrile (buffer B), at a flow
135 rate of 4 ml/min (λ = 230 nm). The purity and identity of each peptide were assessed by: (i)
136 analytical C_{18} reversed-phase HPLC (C_{18} Lichrospher 5 μm, 4 × 200 mm; Merck) using a 60
137 min linear gradient of buffer A with 0-60% of buffer B, at a flow rate of 1 ml/min; and (ii)
138 molecular mass determination by matrix-assisted laser desorption ionization-time of flight
139 (MALDI-TOF) spectrometry (Voyager DE-RP, Perceptive Biosystems Inc.).

140

141   *2.4.   HPLC-based peptide binding assays*
142 Eighty microlitres of a peptide (NF01, NF02, NF03, NF04, Chim1, pep01 or pep02) at a
143 concentration of 1.25 mM in 0.1 M Tris-HCl buffer, pH 8.3, were tested with 10 μl of OTA
144 solution at 0.1 M in acetonitrile, supplemented with 70 μl of 0.1 M Tris-HCl buffer (pH 8.3)
145 and 40 μl acetonitrile. The mixture of peptide and OTA was incubated for 4 h in the dark, at a
146 temperature of 30°C. The reaction medium (200 μl) was then analyzed by C_{18} reversed-phase
147 HPLC (C_{18} Aquapore ODS, 20 μm, 250 × 10 mm; PerkinElmer Life Sciences) by means of a
148 40-min linear gradient of 0.08% (v/v) trifluoroacetic acid/H_2O (buffer A) with 0 to 60% of
149 0.1% (v/v) trifluoroacetic acid/acetonitrile (buffer B), at a flow rate of 1 ml/min (λ = 230 nm).
150 Peptide reactivity with OTA was finally assessed by comparing the peak areas corresponding
151 to free peptide (unreactive peptide) between the test sample of peptide/OTA, and a reference
152 sample of peptide alone (without OTA). It is worth mentioning that results obtained with the
153 reference samples (peptides alone) are similar to those obtained with peptides incubated with
154 irrelevant, unreactive products (data not shown). The identity of free peptides and
155 peptide/OTA complexes was verified by MALDI-TOF mass spectrometry. Binding assays
156 were performed in triplicate.

157

158   *2.5.   Peptide-based competitive enzyme-linked immunosorbent assay (peptide-based*
159   *competitive ELISA)*
160 Polystyrene white microtiter plate wells (Maxisorb LumiNunc, Thermoscientific, USA),
161 coated with the synthetic peptide NFO4 at an optimized concentration of 5 μg/100 μl in
162 carbonate buffer (15 mM Na_2CO_3, 35 mM $NaHCO_3$, 0.2 g/L NaN_3, pH 9.6) were incubated at
163 37°C for 3 h. Non-specific binding sites of the peptide-coated wells were blocked with 5%

164 nonfat dry milk in PBS containing 0.1% Triton X-100 (milk buffer) at room temperature (RT)

165 for 3 h before performing the test. Fifty µl of OTA-HRP (horseradish peroxidase) were added

166 in each well combined with 50 µl of phosphate buffer saline or red wine sample supplemented

167 with unlabeled OTA. The reaction was left for 30 min at RT. After washing unbound OTA,

168 40 µl of luminol (Pierce, France) substrate was added in each well. After 5 min of enzymatic

169 reaction, light emission signals (λmax = 425 nm) were analyzed using an automated

170 microplate luminescence reader (Berthold, France). Light intensity was expressed in Relative

171 Luminescent Unit (RLU). The result obtained is inversely proportional to the concentration of

172 unlabeled OTA. During each test, nonspecific binding (negative control) was determined by

173 using an incubation mixture (OTA-HRP) in which the peptide NFO4 was replaced by 100 µL

174 of carbonate buffer. All the samples were tested in triplicate and the mean of the peak light

175 emission was taken as the final light signal value.

176

177 *2.6. Calculation methods*

178 In order to evaluate the peptide-based competitive assay, a calibration curve was set up by

179 using solutions containing well-defined concentrations of OTA. In that direct competitive

180 peptide-based ELISA, results are expressed in B/Bo dose logarithmic function. B and Bo

181 represent the enzyme-bound activity measured in the presence or absence of competitor,

182 respectively. The standard curve was traced by plotting standard concentrations on x-axis

183 (logarithmic scale) and percentage of maximal binding (express in % of B/B_0) on y-axis (B /

184 Bo = f (log [OTA])). The binding values are obtained by dividing the light intensity of each

185 testing well B (the luminescence measured when OTA-HRP and unlabeled OTA are in

186 competition with NFO4 peptide) by the light intensity of the positive control well B_0

187 (maximum luminescence obtained with OTA-HRP). This method allows the comparison of

188 results between assays performed on different plates or different days. While the absolute

189 light emission may differ from plate to plate or day to day, the percentage of B/Bo values

190 should be reasonably consistent from one plate to the next. All measurements were made in

191 triplicate. The minimum detectable concentration (MDC) was taken as the concentration of

192 competitor (unlabeled OTA) inducing a significant decrease in Bo. The effect of complex

193 matrix was established by testing a red wine sample.

194

195 *2.7. Specificity measurements*

196   The specificity of the peptide immunoassay described previously was controlled by testing its

197   capacity to detect or not ochratoxin B (OTB), another mycotoxin structurally related to OTA.

198   Results are expressed as percentage of cross-reactivity, defined as the ratio (%) of the

199   concentration of OTA and OTB compounds at 50% B/Bo. Cross-reactivity measurement was

200   carried out in triplicates.

201

202   *2.8.   Preparation of matrix samples for peptide EIA: wine pretreatment*

203   In order to study matrix-associated effects, a study with red wine was carried out. A sample of

204   10 ml of wine supplemented (or not) with OTA (1.25 to 15 µg l^{-1}) has been diluted with 10

205   mL of PEG8000 1% - NaHCO$_3$ 5% solution. This mixture has been incubated for 30 min at

206   RT on a rocker. Afterwards, it was centrifuged at 8000 rpm for 15 min. The whole sample is

207   filtered before analysis with the peptide-based enzyme-linked immunosorbent assay.

208

209   3. Results and discussion

210   *3.1.   Rationale of the study*

211   The mycotoxin OTA from *Aspergillus* (e.g., *A. ochraceus*) and *Penicillium* (e.g., *P.*

212   *verrucosum*) genera is a complex organic compound that contains several functional groups,

213   including carbonyl (ester: R^1COOR^2, and amide: $R^1CONHR^2R^3$) and phenol (i.e ϕ-OH)

214   moieties (Fig. 1A). We designed and chemically produce a number of peptides (European

215   patent deposit n°12305269.8, 2012) derived from specific regions of redox proteins (e.g.

216   oxidoreductase) and ABC transporters that potently react -in an HPLC-based binding assay-

217   with more or less complex molecules containing such functional group(s), i.e carbonyl and/or

218   phenol (Table 1a and b). The carbonyl group (i.e C=O) is shared by several types of organic

219   compounds and comprises ketone, aldehyde, ester, amide, carboxylic acid, acid anhydride,

220   enone and acyl halide. We evaluated whether or not these selected peptides would interact

221   with OTA. As shown in Table 2, three peptides (NFO2, NFO3 and NFO4), with related

222   molecular structures (up to 83% sequence identity) derived from human NADH-FMN

223   oxidoreductase significantly interacted with the mycotoxin. The experimental molecular

224   masses, as determined by MALDI-TOF mass spectrometry, were (M+H)$^+$: 1793.17 Da

225   (NFO2), 1722.15 Da (NFO3) and 1598.99 Da (NFO4), consistent with their calculated

226   molecular structures. Among reactive peptides, NFO4 was the most potent compound, with

227   70% binding to OTA in our experimental conditions of binding assay. NFO4 amino acid

228   sequence is provided in Fig. 1B. Fig. 2A shows binding assays with representative HPLC

229   profiles of three reaction media corresponding to NF04 incubated for 4 h at 30°C with lactic

230   acid as negative control (left panel), hydroquinone as positive control (center panel) and OTA

231   (right panel). Interaction of NFO4 with hydroquinone or OTA is highlighted by the

232   disappearance (hydroquinone) or decrease (OTA) of peak area corresponding to free-unbound

233   NFO4. HPLC profiles showing binding of other peptides to OTA are also shown for

234   comparison (Fig. 2B). For example, NFO1 and Chim1 showed binding inferior to 10%, while

235   NFO2 showed binding at 35%.

236   Using NFO4, the threshold of OTA detection was found to be in the same concentration range

237   as the one requested by the European commission regulation (2 µg l^{-1} OTA). Although the

238   potency of OTA detection by NFO4 is actually moderate, one can anticipate that optimizing

239   both NFO4 structure (in a structure-activity relationship study) and the experimental

240   conditions of binding assay could improve sensitivity of peptide-based detection, and yield to

241   the desired mycotoxin detection range in wine. Overall, experimental data obtained strongly

242   suggest that, basically, a peptide-based detection assay of OTA might be a promising

243   approach.

244

245   *3.2.   Peptide-based competitive enzyme-linked immunosorbent assay*

246   Competitive ELISAs are most commonly used to measure various molecules including lipids,

247   hormones, and small peptides if they are present in high enough concentrations. In this study,

248   this type of assay is based on the competition between the analyte of interest, OTA, and an

249   enzyme horseradish peroxidase-conjugated version of the same analyte (referred to as the

250   tracer, OTA-HRP) for a limited number of specific peptide NFO4 binding sites (Fig. 3). The

251   concentration of OTA-HRP is held constant in all wells while the concentration of OTA

252   varies from well-to-well (0 µg l^{-1}, 1.25 µg l^{-1}, 2 µg l^{-1}, 2.5 µg l^{-1}, 5 µg l^{-1}, 10 µg l^{-1} and 15

253   µg l^{-1}). As a result, the amount of tracer that can bind to the peptide NFO4 will be inversely

254   proportional to the amount of analyte in the well – the presence of more analyte means less

255   tracer will be able to bind to the specific peptide.

256   The standard curves obtained for peptide-based competitive ELISA in PBS are shown (Fig.

257   4A). The exponential curve fit for the standard OTA in PBS gives a clear graphical

258   representation of how the competition proceeds. Inhibition starts at 1.25 µg l^{-1} and reaches a

259   maximum at 10 µg l^{-1}. Inhibition is complete which is expected since the tracer is also OTA-

260   based. Half-inhibition occurs at a value of 3.2 µg l^{-1}, which should grossly correspond to the

261   K_d value of NFO4 for OTA. We consider that with this test the LOD for OTA is at 1.25 µg l^{-1}

262   and that differences in OTA concentration can be discriminated between 1.25 and 10 µg l^{-1}.

263   Cross-reactivity measurement of the peptide test was carried out using OTB (Fig. 4A). The

OTB concentration inducing 50% of the maximum possible decrease of the light signal was 8.5 µg l^{-1}, indicating that the affinity of NFO4 for OTB is circa 3-fold lower than for OTA. In addition, free OTB was a worse competitor than OTA for decreasing OTA-HRP signal. Maximal decrease reached 69% instead of 100% for concentrations above 15 µg l^{-1}. At 10 µg l^{-1}, OTA depleted the signal by 89%, whereas OTB reduced it by 47% clearly indicating that OTA detection was better than OTB with this system. Next, we evaluated whether our system could detect OTA from red wine samples. The same range of OTA concentrations was added to red wine samples. The resulting competition curve was compared to that established with pure OTA or OTB in PBS (Fig. 4A). Wine OTA could nicely be detected by the system, with a slight reduction in efficacy which can easily be explained by the enhanced number of non specific compounds co-present in wine samples. Half-inhibition occurred at 5.8 µg l^{-1} and as for OTA in PBS the inhibition was complete. The LOD for OTA in wine was 2 µg l^{-1} (Fig. 4B), which is only slightly higher than OTA in PBS. These results suggested that the NFO4 peptide can be used for detection of OTA in red wine matrices.

4. Conclusions

The European Union (EU) has defined regulatory limits for OTA, *i.e.*, 10 µg l^{-1} in dried vine fruits and instant coffee, 5 µg l^{-1} in cereals and roasted coffee and 2 µg l^{-1} in wine. Here we present a new strategy for detection of this important mycotoxin in various matrices like red wine. We have selected small peptides (12 amino acids) allowing specific recognition of OTA. The peptide named NFO4 was selected in HPLC for its higher affinity for OTA. We have validated this result by a peptide-based competitive ELISA in phosphatase buffer saline and in red wine samples. The peptide-based competitive ELISA showed that NFO4 can discriminate a contamination of 2 µg l^{-1} of OTA in red wine (without preconcentration of the sample on immunoaffinity column). This preliminary study highlights the possibility of using small peptides in biosensor systems (e.g. by electrochemical detection). Modifications of NFO4 peptide sequence may be required in order to further decrease the observed cross-reactivity with OTB which is potentially related to the phenol moiety of OTB. Such a structure-activity relationship study may increase the LOD to the lower value of 1 µg l^{-1} which is the world limit for OTA in red wineIn any case, these preliminary data are quite encouraging and strongly suggest that further work on NFO4 will allow the development of a more sensitive system, either by peptide modification or by OTA preconcentration by an affinity column.

References

298 Alarcon, S.H., Palleschi, G., Compagnone, D., Pascale, M., Visconti, A., Barna-Vetró, I.,
299   2006. Talanta. 69, 1031–1037.

300 Alcaro, MC, Peroni, E, Rovero, P, Papini, A.M., 2003. Curr Protein Pept Sci. 4, 285-90.

301 Ali, W.H., Derrien, D., Alix, F., Pérollier, C., Lépine, O., Bayoudh, S., Chapuis-Hugon, F.,
302   Pichon, V., 2010. J. Chromatogr. A. 1217, 6668-6673.

303 Angelini, E., Bazzo, I., Savino, M., Borgo, M., J Food Prot. 2008.71, 2488-96.

304 Aresta, A., Vatinno, R., Palmisano, F., Zambonin, C.G., 2006., J. Chromatogr. A 1115, 196-
305   201.

306 Belchik, S.M., Xun, L., 2011. Drug Metab Rev. 43, 307-16.

307 Birzele, B., Prange, A., Krämer, J., Food Addit Contam. 2000.17,1027-1035.

308 Blesa, J., Soriano, J.M., Molto, J.C., Manes, J., 2006. Crit. Rev. Food Sci. Nutr. 46, 473-478.

309 Brera, C., De Santis, B., Debegnach, F., Miraglia, M., Yolanda, P., 2008. Mycotoxins in
310   FoodContaminants and Residue Analysis, Comprehensive Analytical Chemistry;
311   Elsevier: Amsterdam,The Netherland, Volume 51, pp. 363–427.

312 Chen, X.M., Kobayashi, H., Sakai, M,. Hirata, H., Asai, T., Ohnishi ,T., Baldermann ,S.,
313   Watanabe, N., 2011. J Plant Physiol. 168, 88-95.

314 Cho, Y.J., Lee, D.H., Kim, D.O., Min, W.K., Bong, K.T., Lee, G.G., Seo, J.H., 2005. J. Agric.
315   Food Chem. 53, 8447-8451

316 Cocchiara, J., Letizia, C.S., Lalko, J., Lapczynski, A., Api, A.M., 2005. Food Chem Toxicol.
317   43, 867-923.

318 Cruz-Aguado, J.A., Penner, G., 2008. Anal. Chem. 80, 8853-8855.

319 Cruz-Aguado, J.A., Penner, G., 2008. J. Agric. Food Chem. 56, 10456-10461.

320 European Commission Regulation N. 123/2005, European Union, Brussels.

321 European Commission Commission Regulation (EU) No. 105/2010. Off. J. Eur. Union. 2010.
322   35:7–8.

323 Franchini, A., Malagoli, D., Ottaviani, E., 2010. Mar Drugs. 16, 658-77.

324 Gerasimov, J.Y., Lai, R.Y., 2010. Chem Commun (Camb). 46, 395-7.

325 Gerberick,G. F., Vassallo, J.D., Bailey, R.E., Chaney, J.G., Morrall, S.W., Lepoittevin, J.P.,
326   2004. Toxicological Sciences. 81, 332-343.

327 Giraudi, G., Anfossi, L., Baggiani, C., Giovannoli,,C., Tozzi, C., 2007. J. Chromatogr. A,
328   1175, 174–180.

329 Girschikofsky, M., Rosenberger, M., Belle, S., Brutschy, M., Waldvogel, SR., Hellmann, R.,
330   Sensors (Basel). 2012. 12, 2018-25.

331 Jorgensen, K., 2005. Food Addit. Contam. 22 (Suppl 1). 26-30.

332 Krska, R., Molinelli, A., 2009. Anal. Bioanal. Chem. 393, 67–71.

333 Liu, X.-P., Deng, Y.-J., Jin, X.-Y., Chen ,L.-G., Juang, J.-H., Shen ,G.-L., Yu, R.-Q., 2009.
334   Anal. Biochem. 389, 63–68.

335 Mateo R, Medina A, Mateo EM, Mateo F, Jiménez M. Int J Food Microbiol. 2007 Oct
336 20;119(1-2):79-83. Epub 2007 Jul 31. Review.

337 Morgan, M.R., McNerney, R., Chan, H.W., J Assoc of Anal Chem. 1983. 66, 1481-1484.

338 O'Brien, E., Dietrich, D.R. 2005. Crit. Rev. Toxicol. 35, 33-60.

339 Pohland, A.E., Nesheim, S., Friedman, L., 1992. Pure Appl. Chem. 64, 1029-1046.

340 Pfohl-Leszkowicz, A., Petkova-Bocharova,T., Chernozemsky, I.N., Castegnaro, M. 2002.
341   Food Addit. Contam. 19, 282-302.

342 Prieto-Simón, B., Campàs, M., Marty, J.-L., Noguer, T. 2008. Biosens. Bioelectron. 23, 995–
343   1002.

344 Quartier, S., Garmyn, M., Becart, S., Goossens, A., 2006. Contact Dermatitis. 55, 257-67.

345 Radi, A.-E., Muñoz-Berbel, X., Lates, V., Marty, J.-L., 2008. Biosens. Bioelectron. 24, 1888–
346   1892

347 Radi, A.-E., Muñoz-Berbel, X., Cortina-Puig, M., Marty, J.-L. 2009. Electrochim. Acta. 54,
348   2180–2184.

349 Ramakrishna, N., Lacey, J., Candlish, A.A., Smith, J.E., Goodbrand, I.A., J Assoc of Anal
350   Chem. 1990. 73, 71-76

351 Ravanshad, M., Sabahi, F., Mahboudi, F., Kazemnejad, A., 2006. Saudi Med J. 27, 31-6.

352 Rusanova, T.Y., Beloglazova, N.V., Goryacheva, I.Y., Lobeau, M., van Peteghem, C., de
353   Saeger, S. 2009. Anal. Chim. Acta. 653, 97–102.

354 Ryan, C.A., Gerberick, G.F., Cruse, L.W., Basketter, D.A., Lea, L., Blaikie, L., Dearman,
355   R.J., Warbrick, E.V., and Kimber, I. 2000. Contact Dermatitis 43, 95-102.

356 Scott, P.M. 1997. Mycotoxins in Grain-Compounds Other than Aflatoxin; Miller, J.D.,
357   Trenholm, H.L.,Eds.; Eagan Press: Saint Paul, MN, USA,; p. 261.

358 Shen, X., Zhang ,G., Zhang, D. 2012. Org Lett. 14, 1744-7.

359 Shim, W., Dzantiev, B.B., Eremin, S.A., Chung, D., 2009. J. Microbiol. Biotechnol.19, 83–
360   92.

361 Smith, J.E., Solomons, G., Lewis, C., Anderson, J.G., 1995. Nat. Toxins 3, 187-192

362 Ueno, Y., Kawamura, O., Sugiura, Y., Horiguchi, K., Nakajima, M,. Yamamoto, K., Sato, S.,
363   IARC Sci Publ. 1991. 115, 71-75.

364 Varga, J., Kozakiewicz, Z., 2006. Trends Food Sci. Technol. 17. 72-81.

365 Visconti, A.; Pascale, M.; Centonze, G. 1999. J. Chromatogr. A. 864, 89–101.

366 Yu, J.C.C., Lai, E. P.C., 2010. Toxins 2, 1536-1553.

367 Zimmerli, B., Dick, R., 1995. J. Chromatogr. B 666, 85-99.

368

369 **Figure captions**

370

371 **Figure 1**: (A) Chemical structure of Ochratoxin A mycotoxin. (B) Amino acid sequence of

372 NFO4. Single letter code.

373

Figure 2 : HPLC-based peptide-based binding assays. (A) Representative HPLC profiles of three reaction media corresponding to NF04 incubation with lactic acid as negative control (left panel), hydroquinone as positive control (center panel) and OTA (right panel). Lactic acid is not detected on the HPLC profile because of lack of absorption at 230 nm. Complexes between NF04 and compounds are not detected on HPLC profiles. (B) Representative HPLC profiles of three peptides incubated with OTA: NFO1 (left), NFO2 (middle), and Chim1 (right). Peak peptide depletions according to control without OTA (not shown) are 7% (NFO1), 35% (NFO2) and 10% (Chim1).

382

Figure 3. Principle of competitive immunoassay with conjugated OTA. (A) The plate is coated with the peptide NFO4. (B) The peptide is then placed in contact with the sample. If the sample contains the specific OTA, the toxin links to the specific peptide and the detection element conjugated with the toxin (usually HRP). (C) The amount of HRP-conjugated toxin that can be fixed is inversely correlated with the amounts of toxin present in the sample. (D) The non-fixed compounds are rinsed away before adding a developing product.

389

Figure 4. (A) Peptide-based competitive ELISA calibration curve. The x-axis represents the calibrator concentration of mycotoxin (OTA or OTB). B and Bo represent the bound enzyme activity measured in the presence or absence of competitor, respectively. Data are average $\pm$ standard deviation, and were fitted by decreasing exponential functions $y = y_0 + a.e^{-bx}$. Y_0 values were <10 for OTA (wine and PBS) and >30 for OTB. (B) Peptide-based competitive ELISA with OTA in wine. The negative control is the luminescence emitted with OTA-HRP without NFO4 peptide. Data are the mean of n=3 $\pm$ standard deviation.

397

398

Table 1a: HPLC-based peptide binding assays. Percentages of peak area depletion are noted. '100' corresponds to 100% binding of peptide to indicated chemical compound. '0' corresponds to a lack of interaction between peptide and organic compound.

Peptides/chemical compounds	NFO1	NFO2	NFO3	NFO4	Chim1
Hydroquinone	100	90	100	100	80
Phtalic anhydride	95	100	100	100	85
Diphenylcyclopropenone	0	98	100	99	85
Cinnamic aldehyde	55	35	100	100	90
Phenylacetaldehyde	80	20	35	100	55
Lactic acid	0	0	0	0	0
Okadaic acid	0	0	0	0	0
Naphtalene	0	0	0	0	0

Table 1b: Chemical structures of organic compounds studied in HPLC-based peptide binding assays.

| Name	MW	Chemical structure	References
Hydroquinone	110.11		Belchik et al., 2011
Phtalic anhydride	148.10		Quartier et al., 2006
Diphenylcyclopropenone	206.25		Ryan et al., 2000
Cinnamic aldehyde	132.16		Cocchiara et al., 2005
Phenylacetaldehyde	120.15		Chen et al., 2011
Lactic acid	90.08		Shen et al., 2012
Okadaic acid	805.00		Franchini et al., 2010

| Naphtalene | 128.17 | | Girschikofsky et al., 2012 |

Table 2: Peptide binding assay. Percentages of peak area depletion are noted. '100' corresponds to 100 % binding of peptide to organic compound. '0' corresponds to a lack of interaction.

Peptides/chemical compounds	NFO1	NFO2	NFO3	NFO4	Chim1
OTA	7	35	40	70	10
Hydroquinone**	100	90	100	100	80
Lactic acid*	0	5	4	7	1

** Positive control ; * Negative control

Figure 1

A

B

NFO4 primary structure

VYMNR KYYKC CK-NH$_2$
 1   5   10 12

Figure 2

Figure 3

A

B

C

D

Y — Peptide NFO4 anti-OTA

■ — OTA

□ ○ — Other compounds (interferences)

— OTA-HRP

— Developper (substrate)

Figure 4

A

B/B$_0$ (%)

Red wine OTA

PBS OTA

PBS OTB

Mycotoxin concentration (µg l^{-1})

B

luminescence (RLU)

Control   0   2   10

OTA concentration (µg l^{-1})